The Recall Desk

Hazard

Cross Contamination recalls

435 recalls in our database tag this hazard, drawn from FDA, USDA FSIS, CPSC, and NHTSA source notices.

What the numbers show

Total
435
Critical
6
Severe
157
Most recent
2026-07-29

Of the 435 cross contamination recalls we have scored against our rubric, 6 (1%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 157 (36%) are Severe.

About this hazard tag

Hazard tags are short, machine-readable labels we attach to every recall to make cross-cutting queries possible — “all cross contamination recalls regardless of agency”, “all listeria recalls in California”, “all airbag recalls in 2025”. The tags are extracted from each recall’s source text during the LLM rewrite step and validated against a fixed schema.

A recall can carry multiple tags — a Listeria recall might also be tagged ready-to-eat and undeclared-allergen. Use the full-text search if you want to combine hazard tags with brand or category filters.

301–325 of 435

  • SevereFDA (Drugs)·D-911-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tadalafil API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tadalafil active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Tadalafil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-947-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ursodiol API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ursodiol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Ursodiol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-944-2015·2015-04-29

    Attix Pharmaceuticals Recalls Trifluridine API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Trifluridine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Trifluridine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-515-2015·2015-04-29

    Attix Pharmaceuticals Recalls Aminopyridine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Aminopyridine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Aminopyridine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-567-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cefazolin Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cefazolin Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Cefazolin Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-593-2015·2015-04-29

    Attix Pharmaceuticals Recalls Clindamycin HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Clindamycin HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Clindamycin HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-796-2015·2015-04-29

    Attix Pharmaceuticals Recalls Mexiletine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Mexiletine HCl active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Mexiletine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-636-2015·2015-04-29

    Attix Pharmaceuticals Recalls Docetaxel Anhydrous Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Docetaxel Anhydrous active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Docetaxel Anhydrous active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-904-2015·2015-04-29

    Attix Pharmaceuticals Recalls Streptomycin Sulfate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Streptomycin Sulfate API because it was repackaged in a facility with penicillin products without adequate separation, creating a cross-contamination risk.

    Product
    Streptomycin Sulfate or Sulphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-594-2015·2015-04-29

    Attix Pharmaceuticals Recalls Clomiphene Citrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Clomiphene Citrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Clomiphene Citrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-797-2015·2015-04-29

    Attix Miconazole Nitrate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Miconazole Nitrate active ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Miconazole Nitrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-819-2015·2015-04-29

    Attix Pharmaceuticals Recalls Nitrofurantoin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Nitrofurantoin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The recall affects lots distributed nationwide to compounding pharmacies and research organizations.

    Product
    Nitrofurantoin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-828-2015·2015-04-29

    Attix Pharmaceuticals Recalls Oxcarbazepine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling oxcarbazepine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Oxcarbazepine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-879-2015·2015-04-29

    Ribavirin Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Ribavirin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Ribavirin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-823-2015·2015-04-29

    Attix Pharmaceuticals Recalls Omeprazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Omeprazole active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Omeprazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-713-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydrocortisone Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling hydrocortisone active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Hydrocortisone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-649-2015·2015-04-29

    Attix Pharmaceuticals Recalls Enzalutamide API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling enzalutamide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Enzalutamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-643-2015·2015-04-29

    Attix Pharmaceuticals Recalls Doxycycline Monohydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Doxycycline Monohydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Doxycycline Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-494-2015·2015-04-29

    Attix Pharmaceuticals Recalls 3,4-Diaminopyridine Due to Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling 3,4-Diaminopyridine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    3,4-Diaminopyridine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-682-2015·2015-04-29

    Fluorescein Sodium Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Fluorescein Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Fluorescein Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-933-2015·2015-04-29

    Tobramycin Sulfate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Tobramycin Sulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Tobramycin Sulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-842-2015·2015-04-29

    Attix Pharmaceuticals Recalls Pimecrolimus Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Pimecrolimus active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Pimecrolimus active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-810-2015·2015-04-29

    Attix Pharmaceuticals Recalls Mycophenolate Mofetil Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Mycophenolate Mofetil active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Mycophenolate Mofetil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-763-2015·2015-04-29

    Lincomycin HCl Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Lincomycin HCl Monohydrate active pharmaceutical ingredient due to potential penicillin cross contamination during repackaging.

    Product
    Lincomycin HCl Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-656-2015·2015-04-29

    Attix Pharmaceuticals Recalls Estriol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Estriol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The product was distributed to compounding pharmacies and research organizations.

    Product
    Estriol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide